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A series of (E) and (Z)-ferrocenyl oxindoles were prepared by coupling substituted oxindoles to
ferrocenylcarboxyaldehyde in the presence of morpholine as a catalyst. The redox behavior of these
isomers was determined by cyclic voltammetry. The effects of the oxindole derivatives on the migration
of human breast cancer cells were evaluated using the wound-healing assay and the Boyden chamber
cell-migration assay. The most potent Z isomers 11b (IC50 = 0.89 mM), 12b (IC50 = 0.49 mM) and 17b
(IC50 = 0.64 mM) could represent attractive new lead compounds for further development for cancer
therapy.
Introduction
Oxindoles are natural indole alkaloids that can be isolated from
plants and are found in mammalian tissues.1 Several compounds
of this class are promising drug candidates for cancer treatment.2,3
Oxindole TMC-95A 1 (Fig. 1), isolated from the plant Apiospora
montagne, has been shown to exhibit cytotoxicity against HCT-
116 andHL-60 cell lines.4 Spiro-oxindoles, such as 2,5 an analogue
of the alkaloid spirotryprostatine A 3, are effective in inhibiting
the growth of cancer cells by inhibiting the interaction between
the oncoprotein MDM2 and tumor suppressor p53.6
Several 2-oxindole derivatives with Z conﬁguration were ob-
tained from the reactions between oxindoles and different aldehy-
des (Fig. 2).7 SU5416 4 and SU6668 5 inhibit angiogenesis in vitro
and are under clinical evaluation for the treatment of cancer.8 The
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Fig. 1 Structures of TMC-95A 1, spiro-oxindole 2, spirotryprostatine A 3.
Fig. 2 Structures of SU5416 4, SU6668 5 and sunitinib 6.
oxindole sunitinib (Sutent R©, 6) has been used successfully to treat
renal cell carcinoma (RCC) and gastrointestinal stromal tumors
(GIST).9
The main molecular target of oxindoles are protein kinases,
enzymes that catalyze the speciﬁc phosphorylation of threonine,
serine (Ser/Thr-speciﬁc kinase) or tyrosine residues (Tyr-speciﬁc
kinase), triggering a series of extracellular and intracellular stim-
uli. These proteins are considered the key switch of intracellular
communication control, regulation and signal transduction.10,11
Deregulation or over expression of these enzymes is associated
with several disorders, including cancer.
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Oxindole-based compounds, such as sunitinib 6, have been
shown to inhibit protein kinases12,13 via competition with the ATP
adenine, by binding to the ATP pocket of the tyrosine kinase
residues of the intracellular domain of the VEGF receptor that
regulates angiogenesis.9,14
The ferrocenyl group has been incorporated into the structure of
a number of biologically active molecules,15 e.g. hydroxytamoxifen
7, in place of a phenyl group, and the resulting ferrocifen (Fc-OH-
Tam, 8)16 is the front-line chemotherapeutic agent for patients
with hormone-dependent breast cancer (Fig. 3).17 Initially, the
mechanism of action of ferrocifen was believed to be similar to
that of tamoxifen, via competitive binding to the estrogen receptor
ERa, thus repressing the estradiol-mediatedDNA transcription in
the tumor tissue.18 However, it has been shown that the activity of
ferrocifen in hormone independent cells is at least in part due to
the redox activity of the ferrocenyl unit.19,20
Fig. 3 Structures of hydroxytamoxifen 7 and ferrocifen 8.
Ferrocenyl-containing systems also proved to be inhibitors of
topoisomerase II (topo II), a key nuclear replication, transcription
andDNA repair enzyme.21 Anumber of ferrocene derivatives have
been found to exhibit antiproliferative activity against strains of
human cancer cells, by forming a complex with topo II, leading to
neoplastic cell death.22
Recently, we reported the reactions of a series of oxindole
derivatives with ferrocene carboxaldehyde (FcC(O)H) in the pres-
ence of KOH as catalyst, yielding predominantly products with E
conﬁguration, together with small amounts of the Z-products.23,24
Spencer et al.25 have tested the unsubstituted compounds 9a and
9b (Fig. 4) against various cancer cell lines and evaluated their
ability to inhibit VEGFR and PDGFR kinases with promising
results.
Fig. 4 Structures of ferrocenyl oxindoles 9a, 9b with E and Z
conﬁgurations.
We report herein the results of our further studies on the
synthesis and redox behavior of a series of (E) and (Z)-ferrocenyl
oxindoles, as well as on the evaluation of the effects of these
compounds on the migration of human breast cancer cells.
By usingmorpholine as the catalyst inmost caseswewere able to
induce changes in reaction selectivity that allowed isolation of the
Z-products for further characterization. The cyclic voltammetry
data suggested that NMR chemical shift analysis alone could not
be used to determine the conﬁguration of the ring substituted
ferrocenyl oxindoles.23,24 Thus, molecular orbital calculations of
the two isomers were carried out and conﬁrmed unequivocally the
Z conﬁguration of these products.
Results and discussion
Synthesis
Compounds 9–17 were condensed with FcC(O)H, in EtOH and
morpholine as catalyst, to give the corresponding ferrocenyl
oxindoles with E (a) and Z (b) conﬁgurations, except for 13
and 15, that yielded only the Z-products. Formation of the E-
or Z-products depended both on the base employed and on the
position of the substituent on the oxindole aromatic ring. The use
of KOH as a catalyst gave the best yields and selectivities for the
E-isomers,23,24 except for compounds 13 (R1 = Cl) and 15 (R1 =
Br), for which only the Z-isomer was detected and isolated. The
presence of morpholine inﬂuences the selectivity favouring the
Z-isomers, as summarized in Table 1.
Although the reactions of the monosubstituted oxindoles 10, 11
and 17 andFcC(O)H in the presence of eitherKOHormorpholine
as catalysts (entries 2, 3 and 9) resulted mainly in E-products,
substantially increased yields of the Z-products (from about 3–
6% to 25–30%) were noted when the reactions were carried out
in the presence of morpholine. Similar results were obtained for
the reactions of the aromatic ring unsubstituted oxindoles 9 and
16 (entries 1 and 8). Interestingly, however, reversal of selectivity
was observed when morpholine was used to catalyze the reactions
of the disubstituted 5,7-dichloro and 5,7-dibromo oxindoles (12
and 14, entries 4 and 6, respectively) with predominant formation
of the Z-products in 67 and 71% yields, respectively. The position
rather than the nature of the substituent determined the outcome
of the reaction: 4,7-dichloro (13) and 4,6-dibromo (15) derivatives
(entries 5 and 7, respectively) reacted to yield only the Z-products,
probably due to steric effects (see below).
Electrochemistry and MO calculations
All compounds were fully characterized by analytical and spec-
troscopic data (see experimental).
The redox behavior of all compounds was evaluated by cyclic
voltammetry at room temperature in acetonitrile/TBAPF6. The
cyclic voltammograms (CV) were obtained in the potential
range from +900 to -2100 mV vs. Ag/AgCl (organic). Selected
voltammetric data are presented in Table 2. In all cases a pair of
reversible waves was observed in the positive region of the CV
that was attributed to the Fc/Fc+ couple. In addition one or two
irreversible processes were observed at -1800 to -2500 mV vs.
FcH/FcH+.
The ferrocenyl (Fc) group was found to be more easily oxidized
in the Z rather than in the E isomers of oxindoles 9–11, 14, 16 and
17. Furthermore the difference in the redox potentials E1/2(E) -
E1/2(Z) varied from 31 to 77 mV, the largest differences being
observed for the N-benzyl derivative 16 (entry 8) and for the
monosubstituted compounds 9–12, 17 (entries 1–3 and 9). The
nature of the substituent affected the redox potential as expected:
This journal is © The Royal Society of Chemistry 2010 Dalton Trans., 2010, 39, 7338–7344 | 7339
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Table 1 Yields obtained using KOH or morpholine as catalysts
Yields (%)a ,b Yields (%)a ,c
Entry Substrate Products E Z E Z
1 9, R1 = R2 = R3 = R4 = R5 = H 9a 9b 95 5 75 20
2 10, R1 = R3 = R4 = R5 = H; R2 = I 10a 10b 93 6 51 27
3 11, R1 = R2 = R3 = R5 = H; R4 = Cl 11a 11b 93 6 52 31
4 12, R1 = R3 = R5 = H; R2 = R4 = Cl 12a 12b 60 3 12 67
5 13, R2 = R3 = R5 = H; R1 = R4 = Cl 13a 13b — 44 — 60
6 14, R1 = R3 = R5 = H; R2 = R4 = Br 14a 14b 70 2 9 71
7 15, R2 = R4 = R5 = H; R1 = R3 = Br 15a 15b — 46 — 44
8 16, R1 = R2 = R3 = R4 = H; R5 = Bn 16a 16b 60 2.5 62 25
9 17, R1 = R2 = R3 = R5 = H; R4 =Me 17a 17b 90 8 50 37
a Yields for isolated products after ﬂash column chromatography on silica-gel. b Reactions with KOH as catalyst (see references 23 and 24). c Reactions
with morpholine as catalyst.
Table 2 Voltammetric data for ferrocenyl oxindoles 9a,b–12a,b; 13b;
14a,b; 15b;16a,b and 17a,b
Isomers and E1/2 (DE)/mV
Entry E Z E1/2(E) - E1/2(Z)/mV
1 9a 9b
150 (100) 94 (83) 56
2 10a 10b
182 (77) 123 (74) 59
3 11a 11b
176 (77) 127 (70) 49
4 12a 12b
199 (86) 168 (91) 31
5 — 13b —
152 (111)
6 14a 14b
208 (73) 169 (102) 39
7 — 15b —
152 (111)
8 16a 16b
187 (69) 110 (70) 77
9 17a 17b
139 (82) 88 (72) 51
electron donor groups made oxidation easier than the electron
withdrawing ones. The cyclic voltammograms of 1 : 1 mixtures of
the two isomers of all compounds exhibited Fc redox potential
values intermediate between E1/2(E) and E1/2(Z).
Compounds derived from oxindoles 13 and 15 (entries 5 and 7),
that were isolated in only one of the isomeric forms (previously
characterized as theE form based on comparisons of the chemical
shifts of all species),23 were surprisingly easy to oxidize, in
comparison to the corresponding disubstituted compounds 12a
(entry 4) and 14a (entry 6), respectively. These results suggested
that these compounds were in fact the Z isomers 13b and 15b and
not the E ones, as previously reported.
Additional evidence for the prevalence of the Z isomers in
these cases was obtained from molecular orbital calculations
(Table 3). The geometries of the ferrocenyl oxindole derivatives
9a,b, 13b and 15b were fully optimized using the B3LYP/6-
31G(d) approach. Relative energies were then calculated with
B3LYP/6-311+G(2d,p) (Table 3). The same calculations were
carried out for the theoretical E isomers derived from the 4,7-
dichloro (13) and 4,6-dibromo (15) oxindoles, isomers 13a and
15a, respectively, for comparison with the isolated Z isomers 13b
and 15b.
TheZ isomer 9b is more stable than the correspondingE isomer
9a by only 0.46 kcal mol-1. However, when the hydrogen atom in
position 4 is substituted by amore voluminous chlorine or bromine
atom the energy difference between the Z and E isomers increases
to about 5 kcal mol-1 (5.03 kcal mol-1 for 13b and 5.46 kcal mol-1
for 15b). This larger energy difference between the two isomers
should account for the isolation uniquely of 13b and 15b, the Z
products. The higher relative energy of the E relative to the Z
isomer may be attributed to stronger steric repulsions between the
ferrocenyl group and the halogen atom inposition 4,whichdistorts
the geometry of the E isomers and reduces conjugation between
the ferrocenyl and the oxindole units. Whereas the Z isomers are
essentially planar, the E isomers are considerably distorted. A
quantitative indication of the increased steric repulsion in the E
isomers is given by the values of the dihedral angles involving
the exocyclic double bond as well as the C3–C4 bond. In the Z
isomers the dihedral angles involving these bonds are close to
zero, indicating complete conjugation between the ferrocenyl and
the oxindole moieties. In contrast, in the E isomers the dihedral
angle involving the exocyclic double bond has values of 6.7, 9.9
and 9.6 degrees for derivatives 9a, 13a and 15a, respectively. The
dihedral angle involving the C3–C3a bond is even more strongly
distorted, with values of 5.7, 22.3 and 24.8 degrees, for derivatives
9a, 13a and 15a, respectively. The very large distortion in the
7340 | Dalton Trans., 2010, 39, 7338–7344 This journal is © The Royal Society of Chemistry 2010
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Table 3 B3LYP/6-311+G(2d,p)//B3LYP/6-31G(d) absolute (a.u.) and relative (kcal mol-1) energies calculated for the 9a,b, 13a,b and 15a,b derivatives
9a (E) 9b (Z) 13a (E) 13b (Z) 15a (E) 15b (Z)
Absolute energy -2127.0080 -2127.0088 -3046.2479 -3046.2560 -7274.0737 -7274.0824
Relative energy 0.46 0 5.03 0 5.46 0
Table 4 Experimental and GIAO B3LYP/6-311+G(2d,p) relative chem-
ical shifts (ppm)a for the oleﬁnic hydrogen of 9a,b, 13b and 15b derivatives
9a (E) 9b (Z) 13b (Z) 15b (Z)
Expt 7.54 7.41 8.30 8.34
GIAO 7.99 7.53 8.84 8.98
a The relative chemical shifts were calculated using the value of 31.82 ppm
calculated for TMS as reference.
E isomers 13a and 15a precludes conjugation between the two
moieties, thereby destabilizing them.
The GIAO approach using the B3LYP/6-311+G(2d,p) method
was employed to calculate the NMR chemical shifts for the fully
optimized geometries (Table 4). Themain interest is in the chemical
shift of the oleﬁnic hydrogen which may show some displacement
depending on the isomer that is being calculated. Table 4 shows
the experimental and calculated 1H NMR chemical shifts of the
oleﬁnic hydrogen for derivatives 9a,b, 13b, 15b. The calculated
values for 13a and 15a (not isolated) are respectively: 8.33 and
8.45. The results agree with the experimental data for 9a and 9b,
i.e., this hydrogen appears at higher frequency in the spectrum
of the E isomer than in that of the Z isomer. In the cases of
compounds 13a,b and 15a,b, however, the calculated values show
opposite trend. This is mainly because the oleﬁnic hydrogen in
the Z isomer undergoes the strong inﬂuence of the halogen atom
in position 4. From 9a to either 13a or 15a the oleﬁnic hydrogen
undergoes a shift of 0.2–0.5 ppm to higher frequency (the H–O
distance decreases from 9a in either 13a or 15a). However, in the
case of the Z isomers, the change in the hydrogen shielding when
going from 9b to either 13b or 15b is much more evident. The
oleﬁnic hydrogen in the neighborhood of the halogen atom (the
H–X distance is much lower than the sum of the van der Waals
radii of H and X) is deshielded by over 1.2 ppm as compared to
the unsubstituted derivative. In the experimental spectra of 13b
and 15b a similar shift of 0.9–1.0 ppm was observed.
Biological evaluation
The effects of the ferrocenyl oxindoles 9a,b–12a,b; 13b; 14a,b; 15b;
16a,b and 17a,b (Table 1) were investigated on the migration of
tumor cells (MDA-MB-231 breast tumor cells), using the wound-
healing assay. Due to the promising potential of these compounds
to inhibit cellmigration in vitro (inhibitions ranging from12 to 75%
at concentrations up to 2 mM) the Boyden chamber cell-migration
assay was also carried out (Table 5).
As can be seen in Table 5, a series of sixteen synthetic ferrocenyl
oxindoles in either E or Z conﬁgurations (Table 1) were evaluated
on inhibiting migration of breast tumor cells. The cell migration
assay results indicate signiﬁcant inhibition by the E and Z isomers
11a, 11b, 12a, 12b, 17a and 17b, with IC50 values varying in the
range of 0.49–1.85 mM. The Z isomer 15b also showed substantial
inhibition with an IC50 value of 1.04 mM. Compounds 9a, 9b, 10a,
Table 5 Chamber cell migration assay withMDA-MB 231 human breast
tumor cells
Compound IC50/mM
9a > 2.0
9b > 2.0
10a > 2.0
10b > 2.0
11a 1.85 ± 0.14
11b 0.89 ± 0.07
12a 1.17 ± 0.10
12b 0.49 ± 0.04
13b > 2.0
14a > 2.0
14b > 2.0
15b 1.04 ± 0.10
16a > 2.0
16b > 2.0
17a 1.66 ± 0.12
17b 0.64 ± 0.05
Evodiamine 0.28 ± 0.02
10b, 13b, 14a, 14b, 16a and 16b have IC50s > 2.0 mM and were
not further explored. Evodiamine (Table 5), a natural product
with potent anti-metastatic properties, was used as a standard
for comparison. Interestingly, the Z isomers 11b (IC50 = 0.89 ±
0.07 mM), 12b (IC50 = 0.49 ± 0.04 mM) and 17b (IC50 = 0.64 ±
0.05 mM) are the most potent compounds of this series, being
from 2.1 to 2.6-fold more potent than the E isomers 11a (IC50 =
1.85 ± 0.14 mM), 12a (IC50 = 1.17 ± 0.10 mM) and 17a (IC50 =
1.66 ± 0.12 mM), respectively (the biological potency of the isomers
11b, 12b and 17b are within factors of about 1.7 to 3 of that
of evodiamine). This observation is in agreement with the fact
that the ferrocenyl (Fc) group of the Z isomers is more easily
oxidized than the corresponding E isomers, as indicated before.
These results indicate that (E/Z) isomerism could, in principle,
play an important role, not only on the redox potential, but also
on the biological properties of these oxindole derivatives.
The development of new anticancer agents is a major challenge
for the pharmaceutical industry.26 Metastatic spread of tumor cells
is one of the most common causes of death in cancer patients,
therefore the development of inhibitors of tumor metastasis is
of great importance. Considering that these compounds inhibit
human breast tumor cell migration, one can foresee the use of such
compounds in cancer therapy in combination with well-known
antiangiogenic agents. In addition, it is important to note that
the ferrocenyl oxindoles studied are structurally simple and easily
accessible, therefore representing new potential lead compounds
for further development in cancer therapy.27,28
Experimental
IR spectra were recorded on a Nicolet Magna 760 (KBr).
1H- and 13C-NMR were recorded on Bruker 250 or 500 MHz
spectrometers. Chemical shifts are reported in ppm relative to
This journal is © The Royal Society of Chemistry 2010 Dalton Trans., 2010, 39, 7338–7344 | 7341
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CDCl3 as internal reference; J values are given in Hz and the
abbreviation q has been used to describe the quaternary carbon
atoms in the 13C-NMRspectra. EImass spectrawere recordedwith
a Q-Tof microMicromass apparatus. Cyclic voltammograms were
obtained on an Epsilon-BAS potentiostat-galvanostat from 1 ¥
10-3 mol L-1 solutions in dry acetonitrile containing 0.1 mol L-1 of
TBAPF6 as supporting electrolyte, at room temperature and under
an argon atmosphere. Some of the compoundswere poorly soluble
in acetonitrile and the measurements were carried out in saturated
solutions. A standard three component systemwas used: a carbon-
glassy working electrode, a platinum wire auxiliary electrode, and
an Ag/AgCl reference electrode for organic media. Ferrocene was
used as an internal standard (E1/2 0.40 V vs. NHE).
Materials and methods (for human cancer cell studies)
Materials. Thehumanmammalian cancer cell lineMDA-MB-
231 was grown in Dulbecco’s modiﬁed Eagle medium (DMEM),
supplemented with 10% fetal bovine serum (FBS), at 37 ◦C
in a humidiﬁed atmosphere containing 5% CO2. Evodiamine is
commercially available from Sigma. All other chemicals and sol-
vents were of the highest grade readily available from commercial
suppliers.
Wound-healing assay. The tumor cells were seeded into 24-
multiwell plates (Becton-Dickinson) and cultivated until the cells
formed a conﬂuent monolayer. Wounds were set by horizontally
scratching the monolayer with a sterile pipette tip. The cells were
thereafter washed twice with phosphate buffered saline (PBS) to
remove detached cells. Growth media was then added containing
different concentrations of the chemical compound and incubated
at 37 ◦C.28 The cells were photographed at the beginning of the
experiment and after 24 and 48 h to assess the progression of cell
migration into the wound.29,30
Chamber cell-migration assay. Cell migrations were assayed
with Boyden chambers [8.0 mm pore size, polyethylene terephtha-
late membrane, FALCON cell culture insert (Becton-Dickinson)].
MDA-MB-231 breast tumor cells were trypsinized and counted.
200 ml of 5–10 ¥ 104 cells in serum-free medium was added to
the upper chamber and 500 ml of medium with 10% fetal bovine
serum (FBS) was added to the lower chamber. The transwells
were incubated for 22 h at 37 ◦C with different concentrations
(usually 6–8) of the synthetic compounds in both the upper and
lower chambers. Cells on the inside of the transwell inserts were
removed with a cotton swab, and cells on the underside of the
insertwere ﬁxed and stained. Photographs of three randomregions
were taken and the number of cells was counted to calculate the
average number of cells that transmigrated. The data are means
of at least three individual experiments carried out in triplicate.
Evodiamine was used as standard in all experiments. Values of
IC50 were independently determined from the collected data (at
least six different concentrations of the compounds) by non-linear
regression analysis.29–31
General procedure for the preparation of the ferrocenyl oxindoles.
All ferrocenyl oxindoles were synthesized following the same pro-
cedure. A mixture of oxindole (0.2 mmol), ferrocenecarboxyalde-
hyde (0.22 mmol), ethanol (5 mL) and 25 mL of morpholine was
allowed to stir under reﬂux for 1 h. The progress of the reactions
was monitored by TLC, employing 20% hexane–ethyl acetate as
eluent.After total consumption of the substrate, the crude reaction
mixture was extracted with ethyl acetate and washed with water.
The organic layer was separated, dried (Na2SO4) and concentrated
in vacuo. TheE andZ products were separated by silica gel column
chromatography, varying the gradient 2% to 50% hexane–ethyl
acetate. The compounds were obtained as red or purple solids,
depending on the aromatic ring substituents; except for 16a and
16b, they decompose at temperatures above 160 ◦C. The yields are
shown in Table 1.
Experimental data
9a. HRMSESI+: [M+H]+∑ Found 330.0575,C19H15ON56Fe+
H requires 330.0581; IR nmax(KBr)/cm-1: 3362, 3122, 3066, 3020,
2902, 2838, 1693, 1621, 1608, 1465, 1338 and 1220; 1H NMR dH
(250 MHz, CDCl3): 4.14 (5H, s), 4.49 (2H, t, J 1.7 Hz), 4.68 (2H,
t, J 1.7 Hz), 6.81 (1H, d, J 7.5 Hz), 6.86 (1H, dd, J 7.5 Hz), 7.10
(1H, td, J 1.0 and 7.5 Hz), 7.54 (1H, s), 7.85 (1H, d, J 7.5 Hz), d
9.28 (1H, br s, NH); 13CNMR dC (62.5MHz, CDCl3): d 69.63 (5 ¥
CH, Cp), 71.12 (2 ¥ CH, Cp), 78.29 (2 ¥ CH, Cp), 109.82 (CH),
121.07 (CH), 122.40 (CH), 123.35 (q), 128.19 (CH); 137.30 (CH),
141.07 (q), 170.17 (q).
9b. HRMS ESI+: [M + H]+ Found 330.0564, C19H15ON56Fe
+ H requires 330.0581; IR nmax(KBr)/cm-1: 3434, 3133, 3064,
3021, 2923, 2850, 1695, 1619, 1600, 1473 and 1211; 1H NMR
dH (250 MHz, CDCl3): 4.20 (5H, s), 4,60 (2H, t, J 1.90 Hz), 5.34
(2H, t, J 1.90 Hz), 6.84 (1H, d, J 7.50 Hz), 7.02 (1H, td, J 1.1
and 7.5 Hz), 7.21 (1H, td, J 1.0 and 7.5 Hz), 7.41 (1H, s), 7.49
(1H, d, J 7.5 Hz), 7,97 (1H, br s, NH); 13C NMR dC (62.5 MHz,
CDCl3): 69.82 (5 ¥ CH, Cp), 72.43 (2 ¥ CH, Cp), 73.56 (2 ¥ CH,
Cp), 104.66 (q), 109.35 (CH), 118.23 (CH), 121.54 (CH), 125.75
(q), 127.43 (CH), 138.38 (CH), 138.84 (CH), 168.15 (q).
10a. HRMSESI+: [M+H]+∑ Found455.9533,C19H14ONI56Fe
+H requires 455.9548; IR nmax(KBr)/cm-1: 3435, 3145, 3101, 8248,
1697, 1618, 1600, 1442, 1223; 1H NMR dH (250 MHz, CDCl3 +
DMSO): 4.26 (5H, s), 4.67 (2H, br s), 4.75 (2H, br s), 6.69 (1H, d,
J 8.2 Hz), 7.53 (1H, d, J 8.2 Hz), 7.71 (1H, s), 8.31 (1H, br s), 8.37
(1H, br s, NH); 13C NMR dC (62.5 MHz, CDCl3 + DMSO): 68.79
(5 ¥ CH, Cp), 70.29 (2 ¥ CH, Cp), 70.76 (2 ¥ CH, Cp), 82.23 (q),
111.05 (CH), 121.30 (q), 123.80 (q), 129.51 (CH), 135.40 (CH),
137.54 (CH), 140.23 (q), 168.23 (q).
10b. HRMSESI+: [M+H]+∑ Found455.9556,C19H14ONI56Fe
+H requires 455.9548; IR nmax(KBr)/cm-1: 3447, 3141, 3097, 2918,
1688, 1615, 1596, 1473, 1201; 1H NMR dH (250 MHz, CDCl3 +
DMSO): 4.21 (5H, s), 4.64 (2H, t, J 1.9 Hz), 5.33 (2H, t, J 1.9 Hz),
6.63 (1H, d, J 8.0 Hz), 7.39 (1H, s), 7.50 (1H, dd, J 1.6 and
8.0 Hz), 7.77 (1H, d, J 1.6 Hz), 7.89 (1H, br s, NH); 13C NMR
dC (62.5 MHz, CDCl3 + DMSO): 68.89 (5 ¥ CH, Cp), 71.56 (2 ¥
CH, Cp), 72.68 (2 ¥ CH, Cp), 82.39 (q), 110.73 (CH), 119.93 (q),
125.66 (CH), 127.10 (q), 134.55 (CH), 138.14 (q), 138.33 (CH),
166.60 (q).
11a. HRMSESI+: [M+H]+∑ Found 364.0203, C19H14ONCl56-
Fe + H requires 364.0113; IR nmax(KBr)/cm-1: 3367, 3170, 3135,
3079, 3002, 2879, 2802, 1695, 1623, 1602, 1481, 1438, 1330, 1205,
1187; 1H NMR dH (250 MHz, CDCl3 + DMSO): 4.21 (5H, s),
4.60 (2H, br s), 4.74 (2H, br s), 6.89 (1H, t, J 8.0 Hz), 7.17 (1H,
d, J 8.0 Hz), 7.71 (1H, s), 7.83 (1H, d, J 8.0 Hz), 8.54 (1H, br s,
7342 | Dalton Trans., 2010, 39, 7338–7344 This journal is © The Royal Society of Chemistry 2010
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NH); 13C NMR dC (62.5 MHz, CDCl3 + DMSO): 70.03 (5 ¥ CH,
Cp), 71.55 (2 ¥ CH, Cp), 71.93 (2 ¥ CH, Cp), 115.24 (q), 120.78
(CH), 122.28 (CH), 122.65 (q), 124.13 (q), 127.90 (CH), 138.09
(q), 140.21 (CH), 169.40 (q).
11b. HRMSESI+: [M+H]+∑ Found 364.0211, C19H14ONCl56-
Fe + H requires 364.0113; IR nmax(KBr)/cm-1: 3446, 3161, 3003,
2880, 1685, 1586, 1481, 1439, 1369, 1189; 1H NMR dH (250 MHz,
CDCl3 + DMSO): 4.20 (5H, s), 4.64 (2H, t, J 1.9 Hz), 5.34 (2H,
t, J 1.9 Hz), 6.96 (1H, t, J 8.0 Hz), 7.19 (1H, d, J 8.0 Hz), 7.43
(1H, s), 7.37 (1H, d, J 8.0 Hz), 7.84 (1H, br s, NH); 13C NMR dC
(62.5 MHz, CDCl3 + DMSO): 68.97 (5 ¥ CH, Cp), 70.50 (2 ¥ CH,
Cp); 70.91 (2 ¥ CH, Cp), 114.13 (q), 119.68 (CH), 121.00 (CH),
122.13 (q), 123.13 (q), 127.07 (CH), 138.11 (CH), 168.70 (q).
12a. HRMSESI+: [M+H]+∑ Found397.9810,C19H13ONCl256-
Fe + H requires 397.9802; IR nmax(KBr)/cm-1: 3445, 3132, 3073,
2971, 1688, 1594, 1577, 1468, 1208, 1162; 1H NMR dH (250 MHz,
CDCl3): 4.26 (5H, s), 4.69 (2H, t, J 1.7 Hz), 4.75 (2H, t, J 1.7 Hz),
7.21 (1H, d, J 1.6 Hz), 7.79 (1H, s); 7.88 (1H, d, J 1.6 Hz), 8.21
(1H, br s, NH); 13C NMR dC (62.5 MHz, CDCl3): 70.20 (5 ¥ CH,
Cp), 71.80 (2 ¥ CH, Cp), 72.57 (2 ¥ CH, Cp), 115.42 (q), 120.95
(CH), 121.44 (q), 125.00 (q), 127.17 (q), 127.22 (CH), 136.40 (q),
142.29 (CH), 168.90 (q).
12b. HRMSESI+: [M+H]+∑ Found397.9825,C19H13ONCl256-
Fe + H requires 397.9802; IR nmax(KBr)/cm-1: 3419, 3112, 2921,
2850, 1697, 1600, 1573, 1448, 1301, 1151; 1H NMR dH (250 MHz,
CDCl3 + DMSO): 4.28 (5H, s), 4.62 (2H, t, J 1.6 Hz), 4.81 (2H,
t, J 1.6 Hz), 7.44 (1H, s), 7.48 (1H, d, J 1.4 Hz), 7.52 (1H, d, J
1.4 Hz), 8.41 (1H, br s, NH); 13C NMR dC (62.5 MHz, CDCl3 +
DMSO): 74.80 (5 ¥ CH, Cp), 77.71 (2 ¥ CH, Cp), 78.75 (2 ¥ CH,
Cp), 119.35 (q), 121.89 (CH), 125.35 (q), 130.68 (CH), 130.86 (q),
133.21 (q), 140.57 (q), 146.71 (CH), 172.27 (q).
13b. HRMSESI+: [M+H]+∑ Found397.9802,C19H13ONCl256-
Fe + H requires 397.9802; IR nmax(KBr)/cm-1: 3481, 3135, 2921,
2850, 1692, 1614, 1578, 1466, 1323, 1146; 1H NMR dH (250 MHz,
CDCl3 + DMSO): 4.10 (5H, s), 4.56 (2H, br s), 5.18 (br s), 6.81
(1H, d, J 8.0Hz), 6.98 (1H, d, J 8.0Hz), 8.30 (1H, s), 9.10 (1H, br s,
NH); 13C NMR dC (62.5 MHz, CDCl3 + DMSO): 68.78 (5 ¥ CH,
Cp), 71.53 (2 ¥ CH, Cp), 72.83 (2¥ CH, Cp), 111.54 (q), 119.41
(q), 120.63 (q), 122.04 (CH), 123.92 (q), 125.65 (CH), 137.14 (q),
142.93 (CH), 165.66 (q).
14a. HRMSESI+: [M+H]+∑ Found485.8755,C19H13ONBr256-
Fe + H requires 485.8791; IR nmax(KBr)/cm-1: 3441, 3135, 3066,
2956, 2848, 1697, 1621, 1599, 1584, 1447, 1227, 1132; 1HNMR dH
(250 MHz, CDCl3 + DMSO): d 4.25 (5H, s), 4.66 (4H, m), 7.76
(1H, s), 7.49 (1H, s), 8.06 (2H, br s); 13C NMR dC (62.5 MHz,
CDCl3 + DMSO): 68.70 (5 ¥ CH, Cp), 70.28 (2 ¥ CH, Cp), 71.04
(2 ¥ CH, Cp), 102.02 (q), 111.95 (q), 122.28 (CH), 124.14 (q),
128.50 (q), 131.01 (CH), 138.63 (q), 139.53 (CH), 167.83 (q).
14b. HRMSESI+: [M+H]+∑ Found485.8771,C19H13ONBr256-
Fe + H requires 485.8791; IR nmax(KBr)/cm-1: 3357, 3127, 3005,
2924, 2854, 1709, 1689, 1591, 1463, 1443, 1207, 1155; 1HNMR dH
(250 MHz, CDCl3 + DMSO): 4.21 (5H, s), 4.68 (2H, t, J 1.6 Hz),
5.34 (2H, t, J 1.6 Hz), 7.36 (1H, d, J 1.4 Hz), 7.43 (1H, s), 7.20
(1H, d, J 1.4 Hz), 7.71 (1H, br s, NH); 13C NMR dC (62.5 MHz,
CDCl3 + DMSO): 67.75 (5 ¥ CH, Cp), 70.68 (2 ¥ CH, Cp), 71.71
(2 ¥ CH, Cp), 100.39 (q), 114.14 (q), 117.96 (CH), 118.19 (q),
126.55 (q), 128.78 (CH), 135.56 (q), 139.83 (CH), 164.95 (q).
15b. HRMSESI+: [M+H]+∑ Found485.8796,C19H13ONBr256-
Fe+ H requires 485.8791; IR nmax(KBr)/cm-1: 3428, 3114, 3081,
2958, 2921, 2852, 1689, 1604, 1581, 1178; 1H NMR dH (250 MHz,
CDCl3 + DMSO): 4.07 (5H, s), 4.49 (2H, t, J 1.9 Hz), 5.11 (2H,
t, J 1.9 Hz), 6.85 (1H, d, J 1.4 Hz), 7.15 (1H, d, J 1.4 Hz), 8.34
(1H, s), 9.91 (1H, br s, NH); 13C NMR dC (62.5 MHz, CDCl3 +
DMSO): 68.26 (5 ¥ CH, Cp), 70.86 (2 ¥ CH, Cp), 72.17 (2 ¥ CH,
Cp), 109.58 (CH), 113.41 (q), 117.64 (q), 118.56 (q), 119.36 (q),
125.54 (CH), 140.78 (q), 140.84 (CH), 165.06 (q).
16a. HRMS ESI+: [M + H]+ Found 420.1057, C26H21ON56-
Fe + H requires 420.1051; mp 184–186 ◦C; IR nmax(KBr)/cm-1:
3442, 3130, 3137, 3079, 1695, 1623, 1604, 1483, 1330, 1187, 1130;
1HNMR dH (250MHz,CDCl3): 4.25 (5H, s), 4.58 (2H, t, J 1.7Hz),
4.77 (2H, t, J 1.7 Hz), 5.00 (2H, s); 6.72 (1H, d, J 7.6 Hz), 6.95
(1H, t, J 7.6 Hz), 7.15 (1H, t, J 7.6 Hz), 7.32 (5H, m), 7.76 (1H,
s), 7.99 (1H, d, J 7.6 Hz); 13C NMR dC (62.5 MHz, CDCl3): 42.65
(CH2), 69.03 (5 ¥ CH, Cp), 70.53 (2 ¥ CH, Cp), 70.74 (2 ¥ CH,
Cp), 108.11 (CH), 120.87 (CH), 121.08 (q), 121.54 (CH), 121.66
(q), 126.36 (CH), 126.58 (CH), 127.50 (CH), 127.82 (CH), 135.42
(q), 137.36 (CH), 141.29 (q), 167.78 (q).
16b. HRMS ESI+: [M + H]+∑ Found 420.1039, C26H21ON56-
Fe + H requires 420.1051; mp 195–197 ◦C; IR nmax(KBr)/cm-1:
3442, 3128, 3052, 2956, 2917, 1695, 1616, 1604, 1484, 1168; 1H
NMR dH (250 MHz, CDCl3): 4.21 (5H, s), 4.58 (2H, t, J 1.9 Hz),
5.00 (2H, s), 5.36 (2H, t, J 1.9Hz), 6.72 (1H, d, J 7.0Hz), 7.00 (1H,
td, J 1.0 and 7.0 Hz), 7.15 (1H, td, J 1.0 and 7.0 Hz), 7.30 (1H,
s), 7.32 (5H, m), 7.50 (1H, d, J 7.0 Hz); 13C NMR dC (62.5 MHz,
CDCl3): 42.00 (CH2), 68.60 (5 ¥ CH, Cp), 71.16 (2 ¥ CH, Cp),
72.32 (2 ¥ CH, Cp), 107.39 (CH), 116.91 (CH), 119.60 (q), 120.52
(CH), 123.38 (q), 126.03 (CH), 126.19 (CH), 127.47 (CH), 135.42
(q), 137.49 (CH), 138.76 (q), 165.05 (q).
17a. HRMS ESI+: [M + H]+∑ Found 344.0709, C20H17ON56-
Fe + H requires 344.0738; IR nmax(KBr)/cm-1: 3461, 3357, 2918,
2833, 1690, 1608, 1594, 1336, 1218, 1189; 1H NMR dH (250 MHz,
CDCl3): 2.35 (3H, s), 4.24 (5H, s), 4.59 (2H, br s), 4.80 (2H, br
s), 6.91–7.06 (2H, m), 7.67 (1H, br s), 7.82 (1H, d, J 2.0 Hz), 8.87
(1H, br s, NH); 13C NMR dC (62.5 MHz, CDCl3): 14.91 (CH3),
68.01 (5 ¥ CH, Cp), 69.52 (2 ¥ CH, Cp), 117.43 (q), 118.24 (CH),
119.20 (CH), 120.01 (q), 122.45 (q), 128.14 (CH), 134.62 (CH),
138.85 (q), 168.27 (q).
17b. HRMS ESI+: [M + H]+∑ Found 344.0734, C20H17ON56-
Fe + H requires 344.0738; IR nmax(KBr)/cm-1: 3466, 3419, 3138,
2917, 2849, 1686, 1626, 1596, 1369, 1206, 1044; 1H NMR dH
(250MHz,CDCl3): 2.30 (3H, s), 4.19 (5H, s), 4.49 (2H, t, J 1.8Hz),
5.34 (2H, t, J 1.8 Hz), 6.95 (1H, t, J 7.4 Hz), 7.04 (1H, d, J 7.4 Hz),
7.34 (1H, t, J 7.4 Hz), 7.39 (1H, s), 8.21 (1H, br s, NH); 13C NMR
dC (62.5 MHz, CDCl3): 15.40 (CH3), 68.56 (5 ¥ CH, Cp), 70.88
(2 ¥ CH, Cp), 72.26 (2 ¥ CH, Cp), 114.60 (CH), 117.73 (q), 119.91
(CH), 124.10 (q), 127.64 (CH), 129.96 (q), 136.24 (CH), 137.11
(q), 166.42 (q).
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